In vivo experiment showed that depletion of CD4(+) T lymphocytes lead to inhibition of antitumor activity and decreased antibodies against MMP-2, indicating that contribution of immune response against MMP-2 might be potential novel tumor methods for cancer therapy (119). This evidence concerns the gene CD4 and neoplasm.